GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Other Gross PPE

CAMP (Camp4 Therapeutics) Other Gross PPE : $15.04 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Other Gross PPE?

Camp4 Therapeutics's Other Gross PPE for the quarter that ended in Dec. 2024 was $15.04 Mil.

Camp4 Therapeutics's quarterly Other Gross PPE declined from Jun. 2024 ($15.59 Mil) to Sep. 2024 ($15.09 Mil) and declined from Sep. 2024 ($15.09 Mil) to Dec. 2024 ($15.04 Mil).

Camp4 Therapeutics's annual Other Gross PPE declined from Dec. 2022 ($18.42 Mil) to Dec. 2023 ($16.35 Mil) and declined from Dec. 2023 ($16.35 Mil) to Dec. 2024 ($15.04 Mil).


Camp4 Therapeutics Other Gross PPE Historical Data

The historical data trend for Camp4 Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Other Gross PPE Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Other Gross PPE
18.42 16.35 15.04

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Jun24 Sep24 Dec24
Other Gross PPE Get a 7-Day Free Trial - 16.35 15.59 15.09 15.04

Camp4 Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Camp4 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.